chapter 99 — references - health library self serve/ppo10e... · r338 chapter 99 references 62....

1. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013.

2. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and ado-lescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010;28:2625–2634.

3. Janeway KA, Place AE, Kieran MW, et al. Future of clinical genomics in pediatric oncology. J Clin Oncol 2013;31:1893–1903.

4. Berg SL, Grisell DL, DeLaney TF, et al. Principles of treatment of pediatric solid tumors. Pediatr Clin North Am 1991;38:249–267.

5. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, pro-spective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplat-in, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004–2011.

6. Blakely ML, Lobe TE, Anderson JR, et al. Does debulking improve sur-vival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? J Pediatr Surg 1999;34:736–741.

7. Simon T, Haberle B, Hero B, et al. Role of surgery in the treatment of pa-tients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 2013;31:752–758.

8. Raney B, Stoner J, Anderson J, et al. Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhab-domyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children’s oncology group. J Pediatr Surg 2010;45:2160–2168.

9. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdo-myosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 1998;34:1050–1062.

10. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosar-coma Study. J Clin Oncol 1995;13:610–630.

11. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203–216.

12. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369:2106–2120.

13. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362: 2202–2211.

14. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treat-ment. Hematol Oncol Clin North Am 2010;24:65–86.

15. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk strati-fication. Curr Opin Pediatr 2005;17:7–13.

16. Goodman MT, Gurney JG, Smith MA, et al. Sympathetic nervous system tumors. In: Ries LAG, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. National Cancer Institute, SEER Program. Bethesda, MD: Na-tional Cancer Institute; 1999: 65–72.

17. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol 2005;23:6459–6465.

18. Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer 1986;57:1887–1893.

19. Maris JM, Kyemba SM, Rebbeck TR, et al. Molecular genetic analysis of familial neuroblastoma. Eur J Cancer 1997;33:1923–1928.

20. Maris JM, Weiss MJ, Mosse Y, et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res 2002;62:6651–6658.

21. Tonini GP, Longo L, Coco S, et al. Familial neuroblastoma: a complex heri-table disease. Cancer Lett 2003;197:41–45.

22. Shojaei-Brosseau T, Chompret A, Abel A, et al. Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France. Pediatr Blood Cancer 2004;42:99–105.

23. Longo L, Panza E, Schena F, et al. Genetic predisposition to familial neuro-blastoma: identification of two novel genomic regions at 2p and 12p. Human Hered 2007;63:205–211.

24. Knudson AG Jr, Strong LC. Mutation and cancer: neuroblastoma and pheo-chromocytoma. Am J Hum Genet 1972;24:514–532.

25. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930–935.

26. Lemire EG, Chodirker BN, Williams GJ, et al. Familial neuroblastoma: re-port of a kindred with later age at diagnosis. J Pediatr Hematol Oncol 1998; 20:489–493.

27. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971–974.

28. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975–978.

29. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967–970.

30. Ogawa S, Takita J, Sanada M, et al. Oncogenic mutations of ALK in neuro-blastoma. Cancer Sci 2011;102:302–308.

31. Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 2004;74:761–764.

32. Mosse YP, Laundenslager M, Khazi D, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004;75:727–730.

33. Raabe EH, Laundeslager M, Winter C, et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 2008;27: 469–476.

34. Nemecek ER, Sawin RW, Park J. Treatment of neuroblastoma in patients with neurocristopathy syndromes. J Pediatr Hematol Oncol 2003;25:159–162.

35. Maris JM, Chatten J, Meadows AT, et al. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. Med Pediatr Oncol 1997;28:1–5.

36. Stovroff M, Dykes F, Teague WG. The complete spectrum of neurocristopa-thy in an infant with congenital hypoventilation, Hirschsprung’s disease, and neuroblastoma. J Pediatr Surg 1995;30:1218–1221.

37. Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen’s disease: a review of the literature. J Clin Oncol 1985;3: 117–120.

38. The I, Murthy AE, Hannigan GE, et al. Neurofibromatosis type 1 gene muta-tions in neuroblastoma. Nat Genet 1993;3:62–66.

39. Blatt J, Olshan AF, Lee PA, Ross JL. Neuroblastoma and related tumors in Turner’s syndrome. J Pediatr 1997;131:666–670.

40. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998;132:398–400.

41. Anderson DJ, Carnahan JF, Michelsohn A, et al. Antibody markers identify a common progenitor to sympathetic neurons and chromaffin cells in vivo and reveal the timing of commitment to neuronal differentiation in the sympa-thoadrenal lineage. J Neurosci 1991;11:3507–3519.

42. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblas-toma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405–416.

43. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neu-roblastoma Pathology Committee. Cancer 1999;86:349–363.

44. Shimada H, Ambros IM, Dehner LP, et al. The International Neuro-blastoma Pathology Classification (the Shimada system). Cancer 1999;86: 364–372.

45. Peuchmaur M, d’Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274–2281.

46. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pa-thology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer 2001;92:2451–2461.

47. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245–248.

48. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121–1124.

49. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111–1116.

50. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264–2279.

51. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289–297.

52. Kaneko Y, Kanda N, Maseki N, et al. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 1987;47:311–318.

53. Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231–235.

54. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581–591.

55. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243–2253.

56. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340: 1954–1961.

57. Brodeur GM, et al. Trk receptor expression and inhibition in neuroblasto-mas. Clin Cancer Res 2009;15:3244–3250.

58. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62:6462–6466.

59. Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307:1062–1071.

60. Vandepoele K, Van Roy N, Staes K, et al. A novel gene family NBPF: intri-cate structure generated by gene duplications during primate evolution. Mol Biol Evol 2005;22:2265–2274.

61. Diskin SJ, Hou C, Glessner JT, et al. Copy number variation at 1q21.1 associ-ated with neuroblastoma. Nature 2009;459:987–991.

C H A P T E R 9 9 — R E F E R E N C E S

Devita_References.indd 337 10/23/14 4:22 AM

R338 Chapter 99 References

62. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27: 1026–1033.

63. De Preter K, Vermeulen J, Brors B, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16:532–1541.

64. Schleiermacher G, Michon J, Huon I, et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN am-plification. Br J Cancer 2007;97:238–246.

65. Mosse YP, Diskin SJ, Wasserman N, et al. Neuroblastomas have distinct ge-nomic DNA profiles that predict clinical phenotype and regional gene ex-pression. Genes Chromosomes Cancer 2007;46:936–949.

66. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide micro-array gene expression-based classification of neuroblastoma patients outper-forms current clinical risk stratification. J Clin Oncol 2006;24:5070–5078.

67. Oberthuer A, Warnat P, Kahlert Y, et al. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Lett 2007;250: 250–267.

68. Tomioka N, Oba S, Ohira M, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008;27:441–449.

69. Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus associ-ated with clinically aggressive neuroblastoma. N Engl J Med 2008;358: 2585–2593.

70. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influ-ence susceptibility to high-risk neuroblastoma. Nat Genet 2009;41:718–723.

71. Wang K, Diskin SJ, Zhang H, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011;469:216–220.

72. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr He-matol Oncol 1999;21:181–189.

73. Timmerman, R. Images in clinical medicine. Raccoon eyes and neuroblas-toma. N Engl J Med 2003;349:e4.

74. Simon T, Niemann CA, Hero B, et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol 2012;54:347–352.

75. Belgaumi AF, Kauffman WM, Jenkins JJ, et al. Blindness in children with neuroblastoma. Cancer 1997;80:1997–2004.

76. Lucky AW, McGuire J, Komp DM. Infantile neuroblastoma presenting with cutaneous blanching nodules. J Am Acad Dermatol 1982;6:389–391.

77. LaBrosse EH, Comoy E, Bohuon C, et al. Catecholamine metabolism in neuroblastoma. J Natl Cancer Inst 1976;57:633–638.

78. Monsaingeon M, Perel Y, Simonnet G, et al. Comparative values of cate-cholamines and metabolites for the diagnosis of neuroblastoma. Eur J Pediatr 2003;162:397–402.

79. Strenger V, Perel Y, Simonnet G, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 2007;48:504–509.

80. O’Meara A, Tormey W, FitzGerald RJ, et al. Interpretation of random uri-nary catecholamines and their metabolites in neuroblastoma. Acta Paediatr 1994;83:88–92.

81. Bourdeaut F, de Carli E, Timsit S, et al. VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Societe Francaise des Cancers de l’Enfant (SFCE). Pediatr Blood Cancer 2009;52:585–590.

82. Wilson J. Neuroimmunology of dancing eye syndrome in children. Dev Med Child Neurol 2006;48:693–696.

83. Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome. Curr Opin Pediatr 2010;22:745–750.

84. Brunklaus A, Pohl K, Zuberi SM, et al. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics 2011;128:e388–e394.

85. Raffaghello L, Conte M, De Grandis E, et al. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. Eur J Paediatr Neurol 2009;13:219–223.

86. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syn-drome in neuroblastoma: clinical outcome and antineuronal antibodies—a report from the Children’s Cancer Group Study. Med Pediatr Oncol 2001;36:612–622.

87. Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 2005;228:275–282.

88. Russo C, Cohn SL, Petruzzi MJ, et al. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997;28:284–288.

89. Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pedi-atr 2001;139:552–559.

90. De Bernardi B, Balwierz W, Bejent J, et al. Epidural compression in neu-roblastoma: Diagnostic and therapeutic aspects. Cancer Lett 2005;228: 283–299.

91. De Bernardi B, Pianca C, Pistamiglio P, et al. Neuroblastoma with sympto-matic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 2001;19:183–190.

92. Poretti A, Grotzer MA. Neuroblastoma with spinal cord compression: is there an emergency treatment of choice? Dev Med Child Neurol 2012;54:297–298.

93. Hoover M, Bowman LC, Crawford SE, et al. Long-term outcome of patients with intraspinal neuroblastoma. Med Pediatr Oncol 1999;32:353–359.

94. Katzenstein HM, Kent PM, London WB, Cohn SL. Treatment and out-come of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 2001;19:1047–1055.

95. Aydin GB, Kutluk MT, Buyukpamukcu M, et al. Neurological complica-tions of neuroblastic tumors: experience of a single center. Childs Nerv Syst 2010;26:359–365.

96. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102:1319–1326.

97. Mueller WP, Coppenrath E, Pfluger T. Nuclear medicine and multimodal-ity imaging of pediatric neuroblastoma. Pediatr Radiol 2013;43:418–427.

98. Sharp SE, Shulkin BL, Gelfand MJ, et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237–1243.

99. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international cri-teria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466–1477.

100. Piccardo A, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scin-tigraphy in stage 3 and 4 neuroblastoma: a pilot study. European journal of nuclear medicine and molecular imaging 2012;39:57–71.

101. Brodeur GM. Are bone marrow aspirates or biopsies the preferred method to detect metastatic neuroblastoma to bone marrow? J Pediatr Hematol Oncol 1998;20:297–298.

102. Gould VE, Wiedenmann B, Lee I, et al. Synaptophysin expression in neuro-endocrine neoplasms as determined by immunocytochemistry. Am J Pathol 1987;126:243–257.

103. Park SJ, Park CJ, Kim S, et al. Detection of bone marrow metastases of neu-roblastoma with immunohistochemical staining of CD56, chromogranin A, and synaptophysin. Appl Immunohistochem Mol Morphol 2010;18:348–352.

104. Treuner J, Schilling FH. Neuroblastoma mass screening: the arguments for and against. Eur J Cancer 1995;31A:565–568.

105. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047–1053.

106. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;346:1041–1046.

107. Morris JK. Screening for neuroblastoma in children. J Med Screen 2002;9:56. 108. Schilling FH, Spix C, Berthold F, et al. Children may not benefit from

neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer Lett 2003;197:19–28.

109. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874–1881.

110. Kushner BH, Kramer K, LaQuaglia MP, et al. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 2003;41:508–515.

111. Franks LM, Bollen A, Seeger RC, et al. Neuroblastoma in adults and adoles-cents: an indolent course with poor survival. Cancer 1997;79:2028–2035.

112. Conte M, Parodi S, De Bernardi B, et al. Neuroblastoma in adolescents: the Italian experience. Cancer 2006;106: 1409–1417.

113. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblas-toma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27:298–303.

114. Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000;22:197–205.

115. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. J Clin Oncol 2000;18:18–26.

116. Castleberry RP, Shuster JJ, Altshuler G, et al. Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited post-operative chemotherapy: a Pediatric Oncology Group study. J Clin Oncol 1992;10:1299–1304.

117. Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of ex-pectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg 2012;256:573–580.

118. Matthay KK. Stage 4S neuroblastoma: what makes it special? J Clin Oncol 1998;16:2003–2006.

119. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group ex-perience—a pediatric oncology group study. J Clin Oncol 1998;16:2007–2017.

120. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Chil-dren’s Cancer Group study. J Clin Oncol 2000;18:477–486.

121. Taggart DR, London WB, Schmidt ML, et al. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 2011;29:4358–4364.


Chapter 99 References R339

146. Adkins ES, Sawin R, Gerbing RB, et al. Efficacy of complete resection for high-risk neuroblastoma: a Children’s Cancer Group study. J Pediatr Surg 2004;39:931–936.

147. Koh CC, Sheu JC, Liang DC, et al. Complete surgical resection plus che-motherapy prolongs survival in children with stage 4 neuroblastoma. Pediatr Surg Int 2005;21:69–72.

148. Tsuchida Y, Yokoyama J, Kaneko M, et al. Therapeutic significance of sur-gery in advanced neuroblastoma: a report from the study group of Japan. J Pediatr Surg 1992;27:616–622.

149. Shorter NA, Davidoff AM, Evans AE, et al. The role of surgery in the man-agement of stage IV neuroblastoma: a single institution study. Med Pediatr Oncol 1995;24:287–291.

150. Medary I, Aronson D, Cheung NK, et al. Kinetics of primary tumor regres-sion with chemotherapy: implications for the timing of surgery. Ann Surg Oncol 1996;3:521–525.

151. McGregor LM, Rao BN, Davidoff AM, et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children’s Research Hospital Experience. Cancer 2005;104:2837–2846.

152. Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuro-blastoma. J Clin Oncol 2004;22:4888–4892.

153. Cecchetto G, Mosseri V, De Bernardi B, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005;23:8483–8489.

154. Bowman LC, Hancock ML, Santana VM, et al. Impact of intensified ther-apy on clinical outcome in infants and children with neuroblastoma: the St Jude Children’s Research Hospital experience, 1962 to 1988. J Clin Oncol 1991;9:1599–1608.

155. Matthay KK, O’Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Chil-dren’s Cancer Group results. Eur J Cancer 1995;31A:572–575.

156. Pritchard J. “Megatherapy” for advanced neuroblastoma—rationale and role. Eur J Cancer 1995;31A:134–136.

157. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiother-apy and autologous bone marrow transplantation versus continued chemo-therapy for metastatic neuroblastoma: a report of two concurrent Children’s Cancer Group studies. J Clin Oncol 1996;14:2417–2426.

158. Yalcin B, Kremer LC, Caron HN, et al. High-dose chemotherapy and autolo-gous haematopoietic stem cell rescue for children with high-risk neuroblas-toma. Cochrane Database Syst Rev 2013;8:CD006301.

159. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autolo-gous stem-cell rescue versus oral maintenance chemotherapy as consolida-tion treatment in patients with high-risk neuroblastoma: a randomised con-trolled trial. Lancet Oncol 2005;6:649–658.

160. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 2009;27:1007–1013.

161. Ladenstein R, Potschger U, Hartman O, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 proce-dures. Bone Marrow Transplant 2008;41:S118–S127.

162. Molina B, Alonso L, Gonzalez-Vicent M, et al. High-dose busulfan and mel-phalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients. Pediatr Hematol Oncol 2011;28:115–123.

163. Valteau-Couanet D, Benhamou E, Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in in-fants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000;25:937–942.

164. Ladenstein R, Potschger U, Luksch R, et al. Final results from the HR-NBL1/SIOPEN trial facour busulphan-melphalan as superior myeloblative therapy (MAT) for high risk neuroblastoma. J Clin Oncol 2011;29:2.

165. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autolo-gous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380–383.

166. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged pe-ripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 2013;14:999–1008.

167. Philip T, Ladenstein R, Zucker JM, et al. Double megatherapy and autolo-gous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993;67:119–127.

168. Grupp SA, Stern JW, Bunin N, et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol 2000;35:696–700.

169. Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000; 18:2567–2575.

170. Moreau LA, Mcgrady P, London WB, et al. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children’s Oncology Group study. Clin Cancer Res 2006;12:5693–5697.

171. Granger M, Grupp SA, Kletzel M, et al. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in

122. Baker DL, Schmidt ML, Cohn Sl, et al. Outcome after reduced chemothe rapy for intermediate-risk neuroblastoma. N Engl J Med 2010;363:1313–1323.

123. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 1998;16:1256–1264.

124. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005;23:8819–8827.

125. Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2011;29:449–455.

126. London WB, Castel V, Monclair T, et al. Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. J Clin Oncol 2011;29: 3286–3292.

127. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12:2607–2613.

128. Castleberry RP, Cantor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1994;12:1616–1620.

129. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuro-blastoma with intensive chemotherapy, radiotherapy, autologous bone mar-row transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341:1165–1173.

130. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol 1997;15:3433–3440.

131. Tweddle DA, Pinkerton CR, Lewis IJ, et al. OPEC/OJEC for stage 4 neu-roblastoma in children over 1 year of age. Med Pediatr Oncol 2001;36: 239–242.

132. Santana VM, Furman WL, Billups CA, et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 2005;23: 4039–4047.

133. Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group Study. J Clin Oncol 2011;29:4351–4357.

134. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three con-secutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003;21:1592–1601.

135. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991;9:1050–1058.

136. Pinkerton CR, Blanc Vincent MP, Bergeron C, et al. Induction chemother-apy in metastatic neuroblastoma—does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur J Cancer 2000;36:1808–1815.

137. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblas-toma: a randomised trial. Lancet Oncol 2008;9:247–256.

138. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early meta-static response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486–2491.

139. Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. J Nucl Med 2013;54:541–548.

140. Schmidt M, Simon T, Hero B, et al. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008;44:1552–1558.

141. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children’s Cancer Group Study. J Clin Oncol 2000;18:4067–4076.

142. Beiske K, Burchill SA, Cheung IY, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009;100:1627–1637.

143. La Quaglia MP, Kushner BH, Heller G, et al. Stage 4 neuroblastoma diag-nosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 1994;29:1162–1165.

144. Haase GM, O’Leary MC, Ramsay NK, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 1991;26:1119–1123.

145. La Quaglia MP, Kushner BH, Su W, et al. The impact of gross total resec-tion on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004;39:412–417.



201. Coppes MJ, Arnold M, Beckwith JB, et al. Factors affecting the risk of contra-lateral Wilms tumor development: a report from the National Wilms Tumor Study Group. Cancer 1999;85:1616–1625.

202. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomato-sis, and the pathogenesis of Wilms’ tumor. Pediatr Pathol 1990;10:1–36.

203. Hennigar RA, O’Shea PA, Grattan-Smith JD. Clinicopathologic features of nephrogenic rests and nephroblastomatosis. Adv Anat Pathol 2001;8:276–289.

204. Bergeron C, Iliescu C, Thiesse P, et al. Does nephroblastomatosis influence the natural history and relapse rate in Wilms’ tumour? A single centre experi-ence over 11 years. Eur J Cancer 2001;37:385–391.

205. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse out-come in favorable histology Wilms’ tumors. Am J Pathol 2001;158:393–398.

206. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tu-mor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2005;23:7312–7321.

207. Perlman EJ, Grundy PE, Anderson JR, et al. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children’s oncology group study. J Clin Oncol 2011;29: 698–703.

208. Green DM, Jaffe N. Wilms’ tumor—model of a curable pediatric malignant solid tumor. Cancer Treat Rev 1978;5:143–172.

209. Madre C, Orbach D, Baudouin V, et al. Hypertension in childhood can-cer: a frequent complication of certain tumor sites. J Pediatr Hematol Oncol 2006;28:659–664.

210. Auldist AW. Wilms’ tumor presenting as a varicocele. J Pediatr Surg 1976; 11:471–472.

211. Gylys-Morin V, Hoffer FA, Kozakewich H, et al. Wilms tumor and nephro-blastomatosis: imaging characteristics at gadolinium-enhanced MR imaging. Radiology 1993;188:517–521.

212. Ehrlich PF, Hamilton TE, Grundy P, et al. The value of surgery in direct-ing therapy for patients with Wilms’ tumor with pulmonary disease. A report from the National Wilms’ Tumor Study Group (National Wilms’ Tumor Study 5). J Pediatr Surg 2006;41:162–167.

213. Metzger ML, Dome JS. Current therapy for Wilms’ tumor. Oncologist 2005;10:815–826.

214. Green DM. Controversies in the management of Wilms tumour - immediate nephrectomy or delayed nephrectomy? Eur J Cancer 2007;43:2453–2456.

215. Petruzzi MJ, Green DM. Wilms’ tumor. Pediatr Clin North Am 1997;44: 939–952.

216. Shamberger RC, Guthrie KA, Ritchey ML, et al. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann Surg 1999;229:292–297.

217. Ritchey ML, Green DM, Breslow NB, et al. Re: Is contralateral exploration of the kidney necessary in patients with Wilms tumor? J Urol 1997;158:186.

218. Ritchey ML, Shamberger RC, Hamilton T, et al. Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms Tumor Study Group. J Urol 2005;174:1519–1521.

219. Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 2001;19:3719–3724.

220. Shamberger RC, Anderson JR, Breslow NE, et al. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg 2010;251:555–558.

221. Hamilton TE, Ritchey ML, Haase GM, et al. The management of synchro-nous bilateral Wilms tumor: a report from the National Wilms Tumor Study Group. Ann Surg 2011;253:1004–1010.

222. Breslow NE, Takashima JR, Ritchey ML, et al. Renal failure in the Denys-Drash and Wilms’ tumor-aniridia syndromes. Cancer Res 2000;60:4030–4032.

223. Breslow NE, et al. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 2005;174:1972–1975.

224. Ritchey ML, Kelalis PP, Haase GM, et al. Preoperative therapy for intracaval and atrial extension of Wilms tumor. Cancer 1993;71:4104–4110.

225. Shamberger RC, Ritchey ML, Haase GM, et al. Intravascular extension of Wilms tumor. Ann Surg 2001;234:116–121.

226. Ritchey ML. The role of preoperative chemotherapy for Wilms’ tumor: the NWTSG perspective. National Wilms’ Tumor Study Group. Semin Urol Oncol 1999;17:21–27.

227. Green DM, Breslow NE, Ii Y, et al. The role of surgical excision in the management of relapsed Wilms’ tumor patients with pulmonary metastases: a report from the National Wilms’ Tumor Study. J Pediatr Surg 1991;26: 728–733.

228. Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of pre-operative therapy in unilateral and nonmetastatic Wilms’ tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study. J Clin Oncol 2001;19:488–500.

229. de Kraker J, Graf N, van Tinteren H, et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms’ tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 2004; 364:1229–1235.

230. Graf N, van Tinteren H, Bergeron C, et al. Characteristics and outcome of stage II and III non-anaplastic Wilms’ tumour treated according to the SIOP trial and study 93-01. Eur J Cancer 2012;48:3240–3248.

a cooperative group setting: a Pediatric Oncology Group study: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2012;59:902–907.

172. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose che-motherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1. Bone Marrow Transplant 2013;48:947–952.

173. Flandin I, Hartmann O, Michon J, et al. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys 2006;64:1424–1431.

174. Bradfield SM, Douglas JG, Hawkins DS, et al. Fractionated low-dose radio-therapy after myeloablative stem cell transplantation for local control in pa-tients with high-risk neuroblastoma. Cancer 2004;100:1268–1275.

175. Kushner BH, O’Reilly RJ, Mandell LR, et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991;9:274–279.

176. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001;19:2821–2828.

177. Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study. Int J Radiat Oncol Biol Phys 2003;56:28–39.

178. More SS, Renuka PS, Pruthvi K, et al. Isolation, purification, and character-ization of fungal laccase from Pleurotus sp. Enzyme Res 2011;2011:248735.

179. Paulino AC. Palliative radiotherapy in children with neuroblastoma. Pediatr Hematol Oncol 2003;20:111–117.

180. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324–1334.

181. Termuhlen AM, Tersak JM, Liu Q, et al. Twenty-five year follow-up of child-hood Wilms tumor: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2011;57:1210–1216.

182. Ries LAG, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute SEER Program; 1999.

183. Grovas A, Fremgen A, Rauck A, et al. The National Cancer Data Base re-port on patterns of childhood cancers in the United States. Cancer 1997;80: 2321–2332.

184. Breslow N, Beckwith JB, Ciol M, et al. Age distribution of Wilms’ tu-mor: report from the National Wilms’ Tumor Study. Cancer Res 1988;48: 1653–1657.

185. Rivera MN, Haber DA. Wilms’ tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005;5:699–712.

186. Dome JS, Coppes MJ. Recent advances in Wilms tumor genetics. Curr Opin Pediatr 2002;14:5–11.

187. Hohenstein P, Hastie ND. The many facets of the Wilms’ tumour gene, WT1. Hum Mol Genet 2006;15:R196–R201.

188. Porteus MH, Narkool P, Neuberg D, et al. Characteristics and outcome of chil-dren with Beckwith-Wiedemann syndrome and Wilms’ tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2000;18:2026–2031.

189. Green DM, Breslow NE, Beckwith JB, et al. Screening of children with hemihypertrophy, aniridia, and Beckwith-Wiedemann syndrome in patients with Wilms tumor: a report from the National Wilms Tumor Study. Med Pediatr Oncol 1993;21:188–192.

190. Scott RH, Walker L, Olsen OE, et al. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch Dis Child 2006;91:995–999.

191. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: re-sults from the First National Wilms’ Tumor Study. Cancer 1978;41:1937–1948.

192. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor—new definitions with prognostic significance: a report from the Na-tional Wilms Tumor Study Group. Am J Surg Pathol 1996;20:909–920.

193. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms’ tumor: results from the fifth National Wilms’ Tumor Study. J Clin Oncol 2006;24:2352–2358.

194. Spreafico F, Collini P, Terenziani M, et al. Renal cell carcinoma in children and adolescents. Expert Rev Anticancer Ther 2010;10:1967–1978.

195. Schmidt D, Harms D, Evers KG, et al. Bone metastasizing renal tumor (clear cell sarcoma) of childhood with epithelioid elements. Cancer 1985;56: 609–613.

196. Wick MR, Ritter JH, Dehner LP. Malignant rhabdoid tumors: a clinico-pathologic review and conceptual discussion. Semin Diagn Pathol 1995;12: 233–248.

197. Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 2009;8:412–416.

198. Biegel JA, Tan L, Zhang F, et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extra-renal rhabdoid tumors. Clin Cancer Res 2002;8:3461–3467.

199. Howell CG, Othersen GB, Kiviat NE, et al. Therapy and outcome in 51 chil-dren with mesoblastic nephroma: a report of the National Wilms’ Tumor Study. J Pediatr Surg 1982;17:826–831.

200. Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 1998;58:5046–5048.



260. Sang DN, Albert DM. Retinoblastoma: clinical and histopathologic features. Hum Pathol 1982;13:133–147.

261. Howard GM, Ellsworth RM. Differential diagnosis of retinoblastoma. A sta-tistical survey of 500 children. II. Factors relating to the diagnosis of retino-blastoma. Am J Ophthalmol 1965;60:618–621.

262. Ellsworth RM. The practical management of retinoblastoma. Trans Am Ophthalmol Soc 1969;67:462–534.

263. Shields JA, Leonard BC, Michelson JB, et al. B-scan ultrasonography in the diagnosis of atypical retinoblastomas. Can J Ophthalmol 1976;11:42–51.

264. Shields CL, Shields JA. Diagnosis and management of retinoblastoma. Cancer Control 2004;11:317–327.

265. Wilson MW, Rodriquez-Galindo C, Billups C, et al. Lack of correlation be-tween the histologic and magnetic resonance imaging results of optic nerve involvement in eyes primarily enucleated for retinoblastoma. Ophthalmology 2009;116:1558–1563.

266. Freeman CR, Esseltine DL, Whitehead VM, et al. Retinoblastoma: the case for radiotherapy and for adjuvant chemotherapy. Cancer 1980;46: 1913–1918.

267. MacKay CJ, Abramson DH, Ellsworth RM. Metastatic patterns of retinoblas-toma. Arch Ophthalmol 1984;102:391–396.

268. Pratt CB, Meyer D, Chenaille P, et al. The use of bone marrow aspirations and lumbar punctures at the time of diagnosis of retinoblastoma. J Clin On-col 1989;7:140–143.

269. Pratt CB, Crom DB, Magill L, et al. Skeletal scintigraphy in patients with bilateral retinoblastoma. Cancer 1990;65:26–28.

270. Martin H, Reese A. Treatment of retinoblastoma (retinal glioma) surgically and by irradiation. Arch Ophthalmol 1942;27.

271. Reese AB, Ellsworth RM. Management of Retinoblastoma. Ann N Y Acad Sci 1964;114:958–962.

272. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005;18:41–53.

273. Pratt CB, Fontanesi J, Lu X, et al. Proposal for a new staging scheme for in-traocular and extraocular retinoblastoma based on an analysis of 103 globes. Oncologist 1997;2:1–5.

274. Chantada G, Doz F, Antoneli CB, et al. A proposal for an international reti-noblastoma staging system. Pediatr Blood Cancer 2006;47:801–805.

275. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002;120:1653–1658.

276. Stannard C, Lipper S, Sealy R, et al. Retinoblastoma: correlation of invasion of the optic nerve and choroid with prognosis and metastases. Br J Ophthal-mol 1979;63:560–570.

277. Fountain TR, Goldberger S, Murphree AL. Orbital development after enu-cleation in early childhood. Ophthal Plast Reconstr Surg 1999;15:32–36.

278. Shields JA, Glazer LC, Mieler WF, et al. Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. Am J Oph-thalmol 1990;109:647–655.

279. Wilson MW, Haik BG, Liu T, et al. Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma. Am J Ophthalmol 2005;140:397–406.

280. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with exter-nal beam radiotherapy or enucleation. Am J Ophthalmol 2002;133:657–664.

281. Shields JA, Parsons H, Shields CL, et al. The role of cryotherapy in the man-agement of retinoblastoma. Am J Ophthalmol 1989;108:260–264.

282. Shields CL, Mashayekhi A, Sun H, et al. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology 2006;113:2087–2092.

283. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Oph-thalmology 2001;108:2116–2121.

284. Hernandez JC, Brady LW, Shields JA, et al. External beam radiation for reti-noblastoma: results, patterns of failure, and a proposal for treatment guide-lines. Int J Radiat Oncol Biol Phys 1996;35:125–132.

285. Kaste SC, Chen G, Fontanesi J, et al. Orbital development in long-term survivors of retinoblastoma. J Clin Oncol 1997;15:1183–1189.

286. Lee CT, Bilton SD, Farniglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005;63:362–372.

287. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survi-vors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008;100:1771–1779.

288. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005;23:2272–2279.

289. Pratt CB, Fontanesi J, Chenaille P, et al. Chemotherapy for extraocular reti-noblastoma. Pediatr Hematol Oncol 1994;11:301–309.

290. Pratt CB, Crom DB, Howarth C. The use of chemotherapy for extraocular retinoblastoma. Med Pediatr Oncol 1985;13:330–333.

291. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local oph-thalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000;18:12–17.

292. Gombos DS, Kelly A, Coen PG, et al. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br J Ophthalmol 2002;86:80–83.

231. Pritchard-Jones K, Moroz V, Vujanic G, et al. Treatment and outcome of Wilms’ tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol 2012;23:2457–2463.

232. Breslow NE, Ou SS, Beckwith JB, et al. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. Cancer 2004;101:1072–1080.

233. Dome JS, Fernandez CV, Mullen EA, et al. Children’s Oncology Group’s 2013 blueprint for research: renal tumors. Pediatr Blood Cancer 2013;60:994–1000.

234. D’Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms’ tumor. Re-sults of the Third National Wilms’ Tumor Study. Cancer 1989;64:349–360.

235. Green DM. The treatment of stages I-IV favorable histology Wilms’ tumor. J Clin Oncol 2004;22:1366–1372.

236. Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 1998;16:3744–3751.

237. Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tu-mor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2007;48:493–499.

238. Malogolowkin M, Spreafico F, Dome JS, et al. Incidence and outcomes of patients with late recurrence of Wilms’ tumor. Pediatr Blood Cancer 2013;60:1612–1615.

239. Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxoru-bicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008;50:236–241.

240. Dome JS, Liu T, Krasin M, et al. Improved survival for patients with recur-rent Wilms tumor: the experience at St. Jude Children’s Research Hospital. J Pediatr Hematol Oncol 2002;24:192–198.

241. Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol 2002;13:460–469.

242. Ha TC, Spreafico F, Graf N, et al. An international strategy to determine the role of high dose therapy in recurrent Wilms’ tumour. Eur J Cancer 2013;49:194–210.

243. Garaventa A, Hartmann O, Bernard JL, et al. Autologous bone marrow transplantation for pediatric Wilms’ tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 1994;22:11–14.

244. Metzger ML, Stewart CF, Freeman BB 3rd, et al. Topotecan is active against Wilms’ tumor: results of a multi-institutional phase II study. J Clin Oncol 2007;25:3130–3136.

245. Venkatramani R, Malogolowkin MH, Mascarenhas L. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevaci-zumab. Pediatr Blood Cancer 2014;61:756–759.

246. Thomas PR, Tefft M, Compaan PJ, et al. Results of two radiation therapy randomizations in the third National Wilms’ Tumor Study. Cancer 1991;68: 1703–1707.

247. Kalapurakal JA, Li SM, Breslow NE, et al. Influence of radiation therapy delay on abdominal tumor recurrence in patients with favorable histology Wilms’ tumor treated on NWTS-3 and NWTS-4: a report from the National Wilms’ Tumor Study Group. Int J Radiat Oncol Biol Phys 2003;57:495–499.

248. Grundy PE, Green DM, Dirks AC, et al. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histol-ogy Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2012;59:631–635.

249. Verschuur A, Van Tinteren H, Graf N, et al. Treatment of pulmonary metas-tases in children with stage IV nephroblastoma with risk-based use of pulmo-nary radiotherapy. J Clin Oncol 2012;30:3533–3539.

250. Kivela T. The epidemiological challenge of the most frequent eye cancer: reti-noblastoma, an issue of birth and death. Br J Ophthalmol 2009;93:1129–1131.

251. Friend SH, Bernards R, Rogeij S, et al. A human DNA segment with proper-ties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643–646.

252. Matsunaga E. Hereditary retinoblastoma: penetrance, expressivity and age of onset. Hum Genet 1976;33:1–15.

253. Mitter D, Ullmann R, Muradyan A, et al. Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions. Eur J Hum Genet 2011;19:947–958.

254. Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lan-cet Oncol 2013;14:327–334.

255. Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012;481:329–334.

256. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retino-blastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262–1267.

257. Moll AC, Imhof SM, Bouter LM, et al. Second primary tumors in patients with retinoblastoma. A review of the literature. Ophthalmic Genet 1997; 18:27–34.

258. Kleinerman RA, Yu CL, Little MP, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol 2012;30:950–957.

259. Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009;101:581–591.



323. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neo-plasms. A familial syndrome? Ann Intern Med 1969;71:747–752.

324. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a famil-ial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233–1238.

325. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992;326:1301–1308.

326. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994;12:925–930.

327. Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 2001;102: 11–17.

328. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteo-sarcoma and deleterious mutations in the RECQL4 gene in Rothmund- Thomson syndrome. J Natl Cancer Inst 2003;95:669–674.

329. Araki N, Uchida A, Kimura T, et al. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop Relat Res 1991;271–277.

330. Scholz RB, Kabisch H, Weber B, et al. Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 1992;9:125–137.

331. Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the reti-noblastoma gene in osteosarcomas. Cancer Res 1994;54:3042–3048.

332. Maelandsmo GM, Berner JM, Florenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas—relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995;72:393–398.

333. Miller CW, Aslo A, Won A, et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 1996;122:559–565.

334. Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 1999;80:199–204.

335. Gokgoz N, Wunder JS, Mousses S, et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 2001;92:2181–2189.

336. Lopez-Guerrero JA, Lopez-Gines C, Pellin A, et al. Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol 2004;13:81–91.

337. Overholtzer M, Rao PH, Favis R, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 2003;100:11547–11552.

338. Nishijo K, Nakayama T, Aoyama T, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer 2004;111:367–372.

339. Bacci G, Ferrari S, Longhi A, et al. Nonmetastatic osteosarcoma of the ex-tremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop Scand 2003;74:449–454.

340. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154–1161.

341. Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 1979;43:2178–2181.

342. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi- Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991;8–14.

343. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32:423–436.

344. Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008;51:163–170.

345. Byun BH, Kong CB, Lim I, et al. Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteo-sarcoma. Skeletal Radiol 2013;42:1673–1681.

346. Quartuccio N, Treglia G, Salsano M, et al. The role of Fluorine-18- Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol 2013;47:97–102.

347. Denecke T, Hundsdorfer P, Misch D, et al. Assessment of histological re-sponse of paediatric bone sarcomas using FDG PET in comparison to mor-phological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 2010;37:1842–1853.

348. Kong CB, Byun BH, Lim I, et al. 18F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteo-sarcoma. Eur J Nucl Med Mol Imaging 2013;40:728–736.

349. Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommen-dations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:137–139.

350. Peabody TD, Simon MA. Making the diagnosis: keys to a successful bi-opsy in children with bone and soft-tissue tumors. Orthop Clin North Am 1996;27:453–459.

351. Inwards CY, Unni KK. Classification and grading of bone sarcomas. Hematol Oncol Clin North Am 1995;9:545–569.

352. Papagelopoulos PJ, Galanis EC, Vlastou C, et al. Current concepts in the evaluation and treatment of osteosarcoma. Orthopedics 2000;23:858–867.

293. Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combi-nation is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 2012;118:5663–5670.

294. Kunkele A, Jurklies C, Wieland R, et al. Chemoreduction improves eye re-tention in patients with retinoblastoma: a report from the German Retino-blastoma Reference Centre. Br J Ophthalmol 2013;97:1277–1283.

295. Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospec-tive study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol 2013;31:1458–1463.

296. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of intraocu-lar retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003;21: 2019–2025.

297. Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997; 104:2101–2111.

298. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemo-therapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 1996;2:1499–1508.

299. Chantada GL, Dunkel IJ, de Davila MT, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Oph-thalmol 2004;88:1069–1073.

300. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjuncti-val carboplatin for intraocular retinoblastoma. Ophthalmology 1999;106: 1947–1950.

301. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infu-sion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004;9:69–73.

302. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct in-traarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115:1398–1404.

303. Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 2012;96:1078–1083.

304. Brennan RC, Federico S, Bradley C, et al. Targeting the p53 pathway in reti-noblastoma with subconjunctival Nutlin-3a. Cancer Res 2011;71:4205–4213.

305. Benavente CA, McEvoy JD, Findelstein D, et al. Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget 2013;4:844–859.

306. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of metastatic retinoblastoma. Ophthalmology 2003;110:1237–1240.

307. Palma J, Sasso DF, Dufort G, et al. Successful treatment of metastatic retino-blastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant 2012;47:522–527.

308. Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 2005;35:763–766.

309. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelog-enous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 2007;114:1378–1383.

310. Weintraub M, Revel-Vilk S, Charit M, et al. Secondary acute myeloid leu-kemia after etoposide therapy for retinoblastoma. J Pediatr Hematol Oncol 2007;29:646–648.

311. Bhagat SP, Bass JK, White ST, et al. Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. Int J Pediatr Otorhinolaryngol 2010;74:1156–1163.

312. Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in chil-dren with retinoblastoma. J Clin Oncol 2012;30:1034–1041.

313. Weintraub N, Rot I, Shoshani N, et al. Participation in daily activities and quality of life in survivors of retinoblastoma. Pediatr Blood Cancer 2011;56:590–594.

314. van Dijk J, Huisman J, Moll AC, et al. Health-related quality of life of child and adolescent retinoblastoma survivors in the Netherlands. Health Qual Life Outcomes 2007;5:65.

315. Gurney JG, Swensen, AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Institute of Health; 1999: 99–110.

316. Heare T, Hensley MA, Dell’Orfano S. Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr 2009;21:365–372.

317. Bielack SS, Carrle D, Hardes J, et al. Bone tumors in adolescents and young adults. Curr Treat Options Oncol 2008;9:67–80.

318. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531–1543.

319. Tucker MA, D’Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radio-therapy and chemotherapy in children. N Engl J Med 1987;317:588–593.

320. Hawkins MM, Wilsom LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996;88:270–278.

321. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125:229–234.

322. MacCarthy A, Bayne AM, Brownbill PA, et al. Second and subsequent tu-mours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer 2013;108:2455–2463.



382. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–790.

383. Bacci G, Longhi A, Bertoni F, et al. Bone metastases in osteosarcoma pa-tients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli expe-rience in 52 patients. Acta Orthop 2006;77:938–943.

384. Anderson PM, Meyers P, Kleinerman E, et al. Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer 2014;61: 238–244.

385. Goldsby RE, Fan TM, Villaluna D, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Eur J Cancer 2013;49:2384–2391.

386. Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemo-therapy for the treatment of osteosarcoma. Cancer 2011;117:1736–1744.

387. Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteo-sarcoma. Pharmacol Ther 2013;137:89–99.

388. Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteo-sarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001;37:32–38.

389. Mason GE, Aung L, Gall S, et al. Quality of life following amputation or limb preservation in patients with lower extremity bone sarcoma. Front Oncol 2013;3:210.

390. Ginsberg JP, Rai SN, Carlson CA, et al. A comparative analysis of functional outcomes in adolescents and young adults with lower-extremity bone sar-coma. Pediatr Blood Cancer 2007;49:964–969.

391. DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005;61:492–498.

392. Mahajan A, Woo SY, Kornguth DG, et al. Multimodality treatment of os-teosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer 2008;50: 976–982.

393. Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 2007;96:118–123.

394. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic fac-tors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003;98:2447–2456.

395. Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after local recurrence of osteosarcoma: the St. Jude Children’s Research Hospital expe-rience (1970-2000). Cancer 2004;100:1928–1935.

396. Berrak SG, Pearson M, Berberoglu S, et al. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 2005;44:215–219.

397. Aad G, Abbott B, Abdallah J, et al. Search for pair production of a new b’ quark that decays into a Z boson and a bottom quark with the ATLAS detec-tor. Phys Rev Lett 2012;109:071801.

398. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706–1712.

399. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419–425.

400. Rodriguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002;24:250–255.

401. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012;23:508–516.

402. Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosar-coma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011;47:895–902.

403. Leary SE, Wozniak AW, Billups CA, et al. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experi-ence. Cancer 2013;119:2645–2653.

404. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a criti-cal review. J Clin Oncol 1994;12:423–431.

405. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 1992;69:698–708.

406. Meyer WH, Kun L, Marina N, et al. Ifosfamide plus etoposide in newly diag-nosed Ewing’s sarcoma of bone. J Clin Oncol 1992;10:1737–1742.

407. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol 2008;26:633–638.

408. de Alava E, Lessnick SL, Sorensen PH. In: Fletcher CDM, Bridge JA, Hogendoorn PC, et al., eds. WHO Classification of Tumours of Soft Tissue and Bone. Lyon: International Agency of Research on Cancer; 2013:305–309.

409. Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011;117:3027–3032.

410. Potikyan G, France KA, Carlson MR, et al. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing’s family tumors. Lab Invest 2008;88:1291–1302.

353. Yarmish G, Klein MJ, Landa J, et al. Imaging characteristics of primary osteo-sarcoma: nonconventional subtypes. Radiographics 2010;30:1653–1672.

354. Antonescu CR, Huvos AG. Low-grade osteogenic sarcoma arising in medul-lary and surface osseous locations. Am J Clin Pathol 2000;114:S90–S103.

355. Revell MP, Deshmukh N, Grimer RJ, et al. Periosteal osteosarcoma: a review of 17 cases with mean follow-up of 52 months. Sarcoma 2002;6:123–130.

356. Nakajima H, Sim FH, Bond JR, et al. Small cell osteosarcoma of bone. Re-view of 72 cases. Cancer 1997;79:2095–2106.

357. Dragoescu E, Jackson-Cook C, Domson G, et al. Small cell osteosarcoma with Ewing sarcoma breakpoint region 1 gene rearrangement detected by inter-phase fluorescence in situ hybridization. Ann Diagn Pathol 2013;17:377–382.

358. Bane BL, Evans HL, Ro JY, et al. Extraskeletal osteosarcoma. A clinicopatho-logic review of 26 cases. Cancer 1990;65:2762–2770.

359. Bridge JA, Nelson M, McComb E, et al. Cytogenetic findings in 73 osteo-sarcoma specimens and a review of the literature. Cancer Genet Cytogenet 1997;95:74–87.

360. Lau CC, Harris CP, Lu XY, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chro-mosomes Cancer 2004;39:11–21.

361. Sadikovic B, Yoshimoto M, Chilton-MacNeill S, et al. Identification of inter-active networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 2009;18:1962–1975.

362. Selvarajah S, Yoshimoto M, Ludovski O, et al. Genomic signatures of chro-mosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res 2008;122:5–15.

363. Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003;38:215–225.

364. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993;72:3227–3238.

365. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemother-apy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600–1606.

366. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5–15.

367. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosar-coma: a randomized prospective trial. J Clin Oncol 1987;5:21–26.

368. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163–2177.

369. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemo-therapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003;21:1574–1580.

370. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosar-coma of the extremity: intensification of preoperative treatment does not in-crease the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003;25:845–853.

371. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Ital-ian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23:8845–8852.

372. Muller CR, Smeland S, Bauer HC, et al. Interferon-alpha as the only ad-juvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 2005;44:475–480.

373. Whelan J, Patterson D, Perisoglou M, et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010;54:350–354.

374. Bielack S, Smeland S, Whelan J, et al. MAP plus maintenance pegylated interferon alpha-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization. Ann Meet Am Soc Clin Oncol 2013;31:Abstract No. LBA10504.

375. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 1998;16:3641–3648.

376. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002;20:426–433.

377. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosar-coma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003;14:1126–1134.

378. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21:2011–2018.

379. Bacci G, Briccoli A, Mercuri M, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998;10:69–76.

380. Harting MT, Blakely ML. Management of osteosarcoma pulmonary metas-tases. Semin Pediatr Surg 2006;15:25–29.

381. Harting MT, Blakely ML, Jaffe N, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with os-teosarcoma. J Pediatr Surg 2006;41:194–199.



443. Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990;8:1514–1524.

444. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing’s sarcoma: The Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J Clin Oncol 1998;16:3628–3633.

445. Craft AW, Cotterill SJ, Bullimore JA, et al. Long-term results from the first UKCCSG Ewing’s Tumour Study (ET-1). United Kingdom Children’s Can-cer Study Group (UKCCSG) and the Medical Research Council Bone Sar-coma Working Party. Eur J Cancer 1997;33:1061–1069.

446. Granowetter L, Worner R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 2009;27:2536–2541.

447. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectoder-mal tumor of bone. N Engl J Med 2003;348:694–701.

448. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988;61:23–32.

449. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664–1674.

450. Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001;85:1646–1654.

451. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 2001;19:1818–1829.

452. Rosen G, Caparros B, Mosende C, et al. Curability of Ewing’s sarcoma and considerations for future therapeutic trials. Cancer 1978;41:888–899.

453. Gaspar N, Rey A, Berard PM, et al. Risk adapted chemotherapy for localised Ewing’s sarcoma of bone: the French EW93 study. Eur J Cancer 2012;48:1376–1385.

454. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2012;30:4148–4154.

455. Obata H, Ueda T, Kawai A, et al. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer 2007;109:767–775.

456. Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide plus vin-cristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing’s sarcoma family of tumors. Cancer 1996;78:901–911.

457. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induc-tion with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006;47:22–29.

458. Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sar-coma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy—a report from the Children’s Oncology Group. Pediatr Blood Cancer 2007;49:894–900.

459. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing’s sar-coma or primitive neuroectodermal tumor of bone: evaluation of combina-tion ifosfamide and etoposide—a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873–2876.

460. Cangir A, Vietti TJ, Gehan EA, et al. Ewing’s sarcoma metastatic at diag-nosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer 1990;66:887–893.

461. Ladenstein R, Potschger U, Le Deley MC, et al. Primary disseminated mul-tifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 2010;28:3284–3291.

462. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children’s Cancer Group Phase II Study 9457—a report from the Children’s Oncology Group. J Clin Oncol 2006;24:152–159.

463. Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose- intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol 1999;17:180–190.

464. Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality ther-apy: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2008;51:334–338.

465. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979-1999. Cancer 2002;94:561–569.

466. Shankar AG, Ashley S, Craft AW, et al. Outcome after relapse in an un-selected cohort of children and adolescents with Ewing sarcoma. Med Pedi-atr Oncol 2003;40:141–147.

467. McLean TW, Hartel C, Young ML, et al. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: the Dana-Farber Cancer Institute/Children’s Hospital experience. J Pediatr Hematol Oncol 1999;21:486–493.

411. Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008;68:2176–2185.

412. Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007;11:421–429.

413. Dela Cruz FS. Cancer stem cells in pediatric sarcomas. Front Oncol 2013;3:168. 414. Lazar A, Abruzzo LV, Pollock RE, et al. Molecular diagnosis of sarcomas:

chromosomal translocations in sarcomas. Arch Pathol Lab Med 2006;130: 1199–1207.

415. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 2007; 254:1–10.

416. Sankar S, Lessnick SL. Promiscuous partnerships in Ewing’s sarcoma. Cancer Genet 2011;204:351–365.

417. Le Deley MC, Delattre O, Schaefer KL, et al. Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuro-ectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010;28:1982–1988.

418. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a re-port from the Children’s Oncology Group. J Clin Oncol 2010;28:1989–1994.

419. Joo J, Christensen L, Warner K, et al. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One 2009;4:e7608.

420. Zwerner JP, Joo J, Warner KL, et al. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 2008;27:3282–3291.

421. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking onco-genic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma. Nat Med 1983;15:750–756.

422. Geryk-Hall M, Hughes DP. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr Oncol Rep 2009;11:446–453.

423. Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarco-mas. Curr Oncol Rep 2009;11:307–313.

424. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662–7671.

425. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing’s sarcoma cell proliferation. Oncogene 2003;22:9282–9287.

426. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129–135.

427. Sneppen O, Hansen LM. Presenting symptoms and treatment delay in osteo-sarcoma and Ewing’s sarcoma. Acta Radiol Oncol 1984;23:159–162.

428. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000;82:667–674.

429. Bernstein M, Kovar H, Paulussen M, et al. Ewing’s sarcoma family of tumors: current management. Oncologist 2006;11:503–519.

430. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 2003;40:276–287.

431. Farley FA, Healey JH, Caparros-Sison B, et al. Lactase dehydrogenase as a tumor marker for recurrent disease in Ewing’s sarcoma. Cancer 1987;59:1245–1248.

432. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177: 229–236.

433. Volker T, Denecke T, Steffen I, et al. Positron emission tomography for stag-ing of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007;25:5435–5441.

434. Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000;27:1305–1311.

435. Hawkins DS, Scheutze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828–8834.

436. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9:275–281.

437. Riopel M, Dickman PS, Link MP, et al. MIC2 analysis in pediatric lympho-mas and leukemias. Hum Pathol 1994;25:396–399.

438. Ozdemirli M, Fanburg-Smith JC, Hartmann DP, et al. Differentiating lym-phoblastic lymphoma and Ewing’s sarcoma: lymphocyte markers and gene rearrangement. Mod Pathol 2001;14:1175–1182.

439. Granter SR, Renshaw AA, Fletcher CD, et al. CD99 reactivity in mesenchy-mal chondrosarcoma. Hum Pathol 1996;27:1273–1276.

440. Pelmus M, Guillou L, Hostein I, et al. Monophasic fibrous and poorly differ-entiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol 2002;26:1434–1440.

441. Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol 2010;11:184–192. 442. Bacci G, Mercuri M, Longhi A, et al. Neoadjuvant chemotherapy for Ewing’s

tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer 2002;38:2243–2251.



495. Cheung IY, Feng Y, Danis K, et al. Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res 2007;13:6978–6983.

496. Schaefer KL, Eisenacher M, Braun Y, et al. Microarray analysis of Ewing’s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008;44:699–709.

497. Ognjanovic S, Linabery AM, Charbonneau B, et al. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 2009;115:4218–4226.

498. Ognjanovic S, Olivier M, Bergemann TL, et al. Sarcomas in TP53 germ-line mutation carriers: a review of the IARC TP53 database. Cancer 2012;118:1387–1396.

499. Gripp KW, SCott CI Jr, Nicholson L, et al. Five additional Costello syn-drome patients with rhabdomyosarcoma: proposal for a tumor screening pro-tocol. Am J Med Genet 2002;108:80–87.

500. Smith AC, Squire JA, Thorner P, et al. Association of alveolar rhabdomyo-sarcoma with the Beckwith-Wiedemann syndrome. Pediatr Dev Pathol 2001;4:550–558.

501. Sung L, Anderson JR, Arndt C, et al. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the intergroup Rhabdomyosarcoma study IV. J Pediatr 2004;144:666–668.

502. Doros L, Yang J, Dehner L, et al. DICER1 mutations in embryonal rhabdo-myosarcomas from children with and without familial PPB-tumor predisposi-tion syndrome. Pediatr Blood Cancer 2012;59:558–560.

503. Grufferman S, Schwartz AG, Ruymann FB, et al. Parents’ use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 1993;4:217–224.

504. Ognjanovic S, Carozza SE, Chow EJ, et al. Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype. Br J Cancer 2010;102:227–231.

505. Von Behren J, Spector LG, Mueller BA, et al. Birth order and risk of childhood cancer: A pooled analysis from five US States. Int J Cancer 2011;128:2709–2716.

506. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78–84.

507. Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyo-sarcomas and related sarcomas. Pathologic aspects and proposal for a new classification—an Intergroup Rhabdomyosarcoma Study. Cancer 1995;76: 1073–1085.

508. Fletcher C, Bridge JA, Hogendoorn P, et al., eds. WHO Classification of Tumors of Soft Tissue and Bone. 4th ed. Lyon: IARC; 2013: 127–134.

509. Qualman S, Lynch J, Bridge J, et al. Prevalence and clinical impact of anapla-sia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Cancer 2008;113:3242–3247.

510. Rudzinski ER, Teot LA, Anderson JR, et al. Dense pattern of embryonal rhab-domyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Am J Clin Pathol 2013;140:82–90.

511. Pappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13:2123–2139.

512. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091–3102.

513. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 2006;130:1454–1465.

514. Chiles MC, Parham DM, Qualman SJ, et al. Sclerosing rhabdomyosarco-mas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children’s Oncology Group. Pediatr Dev Pathol 2005;8:141.

515. Scrable H, Cavanee W, Ghavimi F, et al. A model for embryonal rhabdomyo-sarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A 1989;86:7480–7484.

516. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994;94:445–448.

517. Williamson D, Missiaglia E, de Reynies A, et al. Fusion gene-negative alveo-lar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010;28:2151–2158.

518. Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryo-nal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer 2000;27:337–344.

519. Paulson V, Chandler G, Rakheja D, et al. High-resolution array CGH identi-fies common mechanisms that drive embryonal rhabdomyosarcoma patho-genesis. Genes Chromosomes and Cancer 2011;50:397–408.

520. Shukla N, Ameur N, Yilmaz I, et al. Oncogene mutation profiling of pediat-ric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 2012;18:748–757.

521. van Gaal JC, Flucke UE, Roeffen MH, et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol 2012;30:308–315.

468. Hunold A, WEddeling N, Paulussen M, et al. Topotecan and cyclophos-phamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47:795–800.

469. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol 1995;13:2796–2804.

470. Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topote-can in children with recurrent or refractory solid tumors: a Pediatric Oncol-ogy Group phase II study. J Clin Oncol 2001;19:3463–3469.

471. Casey DA, Wesler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009;53:1029–1034.

472. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intrave-nous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132–139.

473. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carbo-platin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol 2001;23:30–38.

474. Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncol-ogy Group Phase I/II study. J Pediatr Hematol Oncol 1995;17:265–269.

475. Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 1993;11:554–560.

476. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 2009;31:723–729.

477. Rosenthal J, Pawlowska AB. High-dose chemotherapy and stem cell res-cue for high-risk Ewing’s family of tumors. Expert Rev Anticancer Ther 2001;11:251–262.

478. Ladenstein R, Lasset C, Pinkerton R, et al. Impact of megatherapy in chil-dren with high-risk Ewing’s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995;15:697–705.

479. Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer 2004;42:465–470.

480. Shamberger RC, Tarbell NJ, Perez-Atayde AR, et al. Malignant small round cell tumor (Ewing’s-PNET) of the chest wall in children. J Pediatr Surg 1994;29:179–184.

481. Denbo JW, Shannon Orr W, Wu Y, et al. Timing of surgery and the role of adjuvant radiotherapy in Ewing sarcoma of the chest wall: a single-institution experience. Ann Surg Oncol 2012;19:3809–3815.

482. Shamberger RC, Laqualglia MP, Krailo MD, et al. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection. J Thorac Cardiovasc Surg 2000;119:1154–1161.

483. Shamberger RC, LaQuaglia MP, Gebhardt MC, et al. Ewing sarcoma/primi-tive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 2003;238:563–567.

484. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003;55:168–177.

485. Indelicato DJ, Keole SR, Shahlaee AH, et al. Definitive radiotherapy for ew-ing tumors of extremities and pelvis: long-term disease control, limb func-tion, and treatment toxicity. Int J Radiat Oncol Biol Phys 2008;72:871–877.

486. Krasin MJ, Rodriguez-Galindo C, Billups CA, et al. Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2004;60:830–838.

487. Rodriguez-Galindo C, Navid F, Liu T, et al. Prognostic factors for local and dis-tant control in Ewing sarcoma family of tumors. Ann Oncol 2008;19:814–820.

488. Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigat-ing radiotherapy in Ewing’s sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:125–135.

489. Kuttesch JF Jr, Waxler LH, Marcus RB, et al. Second malignancies after Ewing’s sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996;14:2818–2825.

490. Paulussen M, Ahrens S, Craft AW, et al. Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol 1998;16:3044–3052.

491. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tu-mor of bone: analysis of 975 patients from the European Intergroup Coopera-tive Ewing’s Sarcoma Study Group. J Clin Oncol 2000;18:3108–3114.

492. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolida-tion therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol 2001;19:2812–2820.

493. Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol 1997;15:1553–1559.

494. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemo-therapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998;80:1020–1033.



547. Lin C, Donaldson SS, Meza JL, et al. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdo-myosarcoma enrolled in COG D9803—a report from the Children’s Oncol-ogy Group. Int J Radiat Oncol Biol Phys 2012;82:1764–1770.

548. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV ran-domized trial of hyperfractionated radiotherapy in children with rhabdomyo-sarcoma—a report from the IRSG. Int J Radiat Oncol Biol Phys 2001;51: 718–728.

549. Breneman J, Meza J, Donaldson SS, et al. Local control with reduced-dose ra-diotherapy for low-risk rhabdomyosarcoma: a report from the Children’s On-cology Group D9602 study. Int J Radiat Oncol Biol Phys 2012;83:720–726.

550. Walterhouse DO, Meza JL, Breneman JC, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children’s Oncology Group. Pediatr Blood Cancer 2011;57:76–83.

551. Oberlin O, Rey A, Sanchez de Toledo J, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive child-hood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 2012;30:2457–2465.

552. Lager JJ, Lyden ER, Anderson JR, et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosar-coma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 2006;24:3415–3422.

553. Carli M, Colombatti R, Oberlin O, et al. European Intergroup Studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 2004;22: 4735–4742.

554. Kolb EA, Gorlick R, Lock R, et al. Initial testing (stage 1) of the IGF-1 re-ceptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011;56:595–603.

555. Keir ST, Maris JM, Reynolds CP, et al. Initial testing (stage 1) of temozolo-mide by the pediatric preclinical testing program. Pediatr Blood Cancer 2013;60:783–790.

556. Chisholm JC, Marandet J, Rey A, et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 2011;29, 1319–1325.

557. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999;17:3487–3493.

558. Bulterys M, Goodman M, Smith M, Buckley J. In: Ries LAG, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute; 1999.

559. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008;112:416–432.

560. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012;59:776–779.

561. Darbari A, Sabin KM, Shapiro CN, et al. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003;38:560–566.

562. Finegold MJ, Egler RA, Goss JA, et al. Liver tumors: pediatric population. Liver Transpl 2008;14:1545–1556.

563. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist 2008;13: 812–820.

564. Ikeda H, Hacitanda Y, Tanimura M, et al. Development of unfavorable hepatoblastoma in children of very low birth weight: results of a surgical and pathologic review. Cancer 1998;82:1789–1796.

565. Reynolds P, Urayama KY, Von Behren J, et al. Birth characteristics and hepa-toblastoma risk in young children. Cancer 2004;100:1070–1076.

566. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC muta-tions in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr 2005;147:263–266.

567. Sanders RP, Furman WL. Familial adenomatous polyposis in two brothers with hepatoblastoma: implications for diagnosis and screening. Pediatr Blood Cancer 2006;47:851–854.

568. Hoyme HE, Seaver LH, Jones KL, et al. Isolated hemihyperplasia (hemi-hypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet 1998;79:274–278.

569. Maruyama K, Ikeda H, Koizumi T. Hepatoblastoma associated with trisomy 18 syndrome: a case report and a review of the literature. Pediatr Int 2001; 43:302–305.

570. Kitanovski L, Ovcak Z, Jazbec J. Multifocal hepatoblastoma in a 6-month-old girl with trisomy 18: a case report. J Med Case Rep 2009;3:8319.

571. Tomlinson GE, Kappler R. Genetics and epigenetics of hepatoblastoma. Pediatr Blood Cancer 2012;59:785–792.

572. Giardiello FM, Offerhaus GJ, Krush AJ, et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr 1991;119:766–768.

573. Aretz S, Koch A, Uhlhaas S, et al. Should children at risk for familial ad-enomatous polyposis be screened for hepatoblastoma and children with ap-parently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr Blood Cancer 2006;47:811–818.

574. Tomlinson GE, Douglass EC, Pollock BH, et al. Cytogenetic evaluation of a large series of hepatoblastoma:numerical abnormalities with recurring aber-rations involving 1q12-q21. Genes Chromosomes Cancer 2005;44:177–184.

522. Newton WA Jr, Soule EH, Hamoudi AB, et al. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 1988;6:67–75.

523. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pedi-atr Hematol Oncol 1997;19:483–491.

524. Williamson D, Ly YJ, Gordon T, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 2005;23:880–888.

525. Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012;30: 1670–1677.

526. Flamant F,Couanet D, McDowell H. Rhabdomyosarcoma in Children: Clin-ical Symptoms, Diagnosis, and Staging. Boca Raton, FL: CRC Press; 1991.

527. Spunt SL, Lobe TE, Pappo AS, et al. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. J Pediatr Surg 2000;35:309–316.

528. Weiss AR, Lyden ER, Anderson JR, et al. Histologic and clinical character-istics can guide staging evaluations for children and adolescents with rhab-domyosarcoma: a report From the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 2013;31:3226–3232.

529. Federico SM, Spunt SL, Krasin MJ, et al. Comparison of PET-CT and con-ventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer 2013;60:1128–1134.

530. Dharmarajan KV, Wexler LH, Gavane S, et al. Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2012;84:996–1002.

531. Spunt SL, Anderson JR, Teot LA, et al. Routine brain imaging is unwarranted in asymptomatic patients with rhabdomyosarcoma arising outside of the head and neck region that is metastatic at diagnosis: a report from the Intergroup Rhabdomyosarcoma Study Group. Cancer 2001;92:121–125.

532. Wiener ES, Anderson JR, Ojimba JI, et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyo-sarcoma? Semin Pediatr Surg 2001;10:146–152.

533. De Corti F, Dall’Igna P, Bisogno G, et al. Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. Pediatr Blood Cancer 2009;52:51–54.

534. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyo-sarcoma Study-I. A final report. Cancer 1988;61:209–220.

535. Lawrence W Jr, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyo-sarcoma Study Group. Children’s Cancer Study Group. Pediatric Oncology Group. Cancer 1997;80:1165–1170.

536. Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma. In: Poplack DG, PIzzo PA, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams and Wilkins; 2011: 923–953.

537. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012;59:5–10.

538. Meza JL, Anderson J, Pappo AS, et al. Analysis of prognostic factors in pa-tients with nonmetastatic rhabdomyosarcoma treated on intergroup rhab-domyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol 2006;24:3844–3851.

539. Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a re-port from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 2011;29:1312–1318.

540. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cy-clophosphamide compared with vincristine, actinomycin, and cyclophos-phamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol 2009;27:5182–5188.

541. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdo-myosarcomas: results of a pooled analysis from United States and European Cooperative Groups. J Clin Oncol 2008;26:2384–2389.

542. Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives un-favorable outcome for children with rhabdomyosarcoma: A children’s oncol-ogy group report. Pediatr Blood Cancer 2013;60:1411–1417.

543. Hays DM, Lawrence W Jr, Wharam M, et al. Primary reexcision for patients with ‘microscopic residual’ tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg 1989;24:5–10.

544. Viswanathan AN, Grier HE, Litman HJ, et al. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. Int J Ra-diat Oncol Biol Phys 2004;58:1208–1214.

545. Cecchetto G, Bisogno G, De Corti F, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies. Cancer 2007;110: 2561–2567.

546. Raney RB, Anderson JR, Brown KL, et al. Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2010;55:612–616.



602. Arnaoutakis DJ, Mavros MN, Shen F, et al. Recurrence patterns and prog-nostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol 2014;21:147–154.

603. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379: 1245–1255.

604. Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblas-toma: a combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr 2005;146:204–211.

605. Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Can-cer 2002;94:1111–1120.

606. Kishi Y, Hasegawa K, Sugawara Y, et al. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical re-section. Int J Hepatol 2001;2011:728103.

607. Chow PK. Resection for hepatocellular carcinoma: is it justifiable to restrict this to the American Association for the Study of the Liver/Barcelona Clinic for Liver Cancer criteria? J Gastroenterol Hepatol 2012;27:452–457.

608. Chen JC, Chen CC, Chen WJ, et al. Hepatocellular carcinoma in chil-dren: clinical review and comparison with adult cases. J Pediatr Surg 1998;33:1350–1354.

609. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach—results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol 2000;18:3819–3828.

610. Perilongo G, Shafford E, Mailbach R, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the Interna-tional Society of Paediatric Oncology—SIOPEL 2. Eur J Cancer 2004;40: 411–421.

611. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblas-toma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004;42:74–83.

612. Faraj W, Dar F, Marangoni G, et al. Liver transplantation for hepatoblas-toma. Liver transplantation 2008;14:1614–1619.

613. Hery G, Franchi-Abella S, Habes D, et al. Initial liver transplantation for unresectable hepatoblastoma after chemotherapy. Pediatr Blood Cancer 2011;57:1270–1275.

614. Reyes JD, Carr B, Dvorchik I, et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adoles-cence. J Pediatr 2000;136:795–804.

615. Pham TH, Iqbal CW, Grams JM, et al. Outcomes of primary liver cancer in children: an appraisal of experience. J Pediatr Surgery 2007;42:834–839.

616. Sevmis S, Karakayali H, Ozcay F, et al. Liver transplantation for hepatocel-lular carcinoma in children. Pediatr Transplant 2008;12:52–56.

617. Ismail H, Broniszczak D, Kalicinski P, et al. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant 2009;13:682–692.

618. Romano F, Stroppa P, Bravi M, et al. Favorable outcome of primary liver transplantation in children with cirrhosis and hepatocellular carcinoma. Pediatr Transplant 2011;15:573–579.

619. McAteer JP, Goldin AB, Healey PJ, et al. Surgical treatment of primary liver tumors in children: Outcomes analysis of resection and transplantation in the SEER database. Pediatr Transplant 2013;17:744–750.

620. Ni JY, Liu SS, Xu LF, et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:653–659.

621. Malogolowkin MH, Stanley P, Steele DA, et al. Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 2000;18: 1279–1284.

622. Arcement CM, Towbin RB, Meza MP, et al. Intrahepatic chemoemboliza-tion in unresectable pediatric liver malignancies. Pediatr Radiol 2000;30: 779–785.

623. Czauderna P, Zbrzezniak G, Narozanski W, et al. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular car-cinoma in children. Pediatr Blood Cancer 2006;46:825–828.

624. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 2013;87: 22–32.

625. Dawson LA. Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol 2011;21:241–246.

626. Habrand JL, Nehme D, Kalifa C, et al. Is there a place for radiation therapy in the management of hepatoblastomas and hepatocellular carcinomas in children? Int J Radiat Oncol Biol Phys 1992;23:525–531.

627. Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxo-rubicin for standard-risk hepatoblastoma. N Engl J Med 2009;361:1662–1670.

628. Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010;28: 2584–2590.

629. Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemother-apy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 2013;14:834–842.

575. Parada LA, Limon J, Illiszko M, et al. Cytogenetics of hepatoblastoma: fur-ther characterization of 1q rearrangements by fluorescence in situ hybrid-ization: an international collaborative study. Med Pediatr Oncol 2000;34: 165–170.

576. Schneider NR, Cooley LD, Finegold MJ, et al. The first recurring chromo-some translocation in hepatoblastoma: der(4)t(1;4)(q12;q34). Genes Chro-mosomes Cancer 1997;19:291–294.

577. Tanimura M, Matsui I, Abe J, et al. Increased risk of hepatoblastoma among immature children with a lower birth weight. Cancer Res 1998;58: 3032–3035.

578. Spector LG, Feusner JH, Ross JA. Hepatoblastoma and low birth weight. Pediatr Blood Cancer 2004;43:706.

579. Fiegel HC, Gluer S, Roth B, et al. Stem-like cells in human hepatoblastoma. J Histochem Cytochem 2004;52:1495–1501.

580. Ruck P, Xiao JC. Stem-like cells in hepatoblastoma. Med Pediatr Oncol 2002;39:504–507.

581. Lopez-Terrada D, Alaggio R, de Davila MT, et al. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol 2014;27:472–291.

582. Malogolowkin MH, Katzenstein HM, Meyers RL, et al. Complete surgi-cal resection is curative for children with hepatoblastoma with pure fe-tal histology: a report from the Children’s Oncology Group. J Clin Oncol 2011;29:3301–3306.

583. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer 2008;44:545–550.

584. Russo P, Biegel JA. SMARCB1/INI1 alterations and hepatoblastoma: another extrarenal rhabdoid tumor revealed? Pediatr Blood Cancer 2009;52:312–313.

585. Navarro C, Corretger JM, Sancho A, et al. Paraneoplasic precocious puberty. Report of a new case with hepatoblastoma and review of the literature. Can-cer 1985;56:1725–1729.

586. Shafford EA, Pritchard J. Extreme thrombocytosis as a diagnostic clue to hepatoblastoma. Arch Dis Child 1993;69:171.

587. Komura E, Matsumura T, Kato T, et al. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998;16:329–333.

588. Katzenstein HM, Krailo MD, Malogolowkin MG, et al. Hepatocellular carci-noma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol 2002; 20:2789–2797.

589. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002;20:2798–2804.

590. Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children’s Cancer Group. J Clin Oncol 1997;15:1190–1197.

591. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic fac-tors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002; 95:172–182.

592. Cistaro A, Treglia G, Pagano M, et al. A comparison between (18) F-FDG PET/CT imaging and biological and radiological findings in restaging of hepatoblastoma patients. Biomed Res Int 2013;2013:709037.

593. McCarville MB, Roebuck DJ. Diagnosis and staging of hepatoblastoma: im-aging aspects. Pediatr Blood Cancer 2012;59:793–799.

594. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubi-cin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000;18: 2665–2675.

595. Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;53:1016–1022.

596. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma—results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000;36:1418–1425.

597. Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 2007;37:123–132.

598. Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pre-treatment extent of disease system in hepatoblastoma: results from the Inter-national Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 2005;23:1245–1252.

599. Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treat-ment of hepatoblastoma in the modern era—recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 2005;41:1031–1036.

600. Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. Eur J Cancer 2012;48:1543–1549.

601. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, et al. Small cell un-differentiated variant of hepatoblastoma: adverse clinical and molecular fea-tures similar to rhabdoid tumors. Pediatr Blood Cancer 2009;52:328–334.



and bleomycin in pediatric germ-cell tumors: a Children’s Oncology Group study. Cancer 2005;104:841–847.

650. Malogolowkin MH, Krailo M, Marina N, et al. Pilot study of cisplatin, etopo-side, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the children’s oncology group (COG). Pediatr Blood Cancer 2013;60:1602–1605.

651. Rescorla FJ. Pediatric germ cell tumors. Semin Pediatr Surg 2012;21:51–60. 652. Altman RP, Randolph JG, Lilly JR. Sacrococcygeal teratoma: Ameri-

can Academy of Pediatrics Surgical Section Survey-1973. J Pediatr Surg 1974;9:389–398.

653. Rescorla FJ, Sawin RS, Coran AG, et al. Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Childrens Cancer Group. J Pediatr Surg 1998;33:171–176.

654. Rescorla F, Billmore D, Stolar C, et al. The effect of cisplatin dose and surgi-cal resection in children with malignant germ cell tumors at the sacrococ-cygeal region: a pediatric intergroup trial (POG 9049/CCG 8882). J Pediatr Surg 2001;36:12–17.

655. Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol 2006;24:2544–2548.

656. Schlatter M, Rescorla F, Giller R, et al. Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children’s Cancer Group/Pediatric Oncology Group. J Pediatr Surg 2003;38:319–324.

657. Rodriguez-Galindo C, Frailo M, Frazier L, et al. Children’s Oncology Group’s 2013 blueprint for research: rare tumors. Pediatr Blood Cancer 2013;60: 1016–1021.

658. Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004;39:424–429.

659. Cushing B, Giller R, Ablin A, et al. Surgical resection alone is effective treat-ment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children’s cancer group. Am J Obstet Gynecol 1999;181:353–358.

660. Mann JR, Gray ES, Thornton C, et al. Mature and immature extracranial teratomas in children: the UK Children’s Cancer Study Group Experience. J Clin Oncol 2008;26:3590–3597.

661. Dark GG, Bower M, Newlands ES, et al. Surveillance policy for stage I ovar-ian germ cell tumors. J Clin Oncol 1997;15:620–624.

662. Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children’s Can-cer Study Group’s second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000;18:3809–3818.

663. Schwartz CL, Wexler LH, Devidas M, et al. P9754 therapeutic intensifica-tion in non-metastatic osteosarcoma: A COG trial. Ann Meet Am Soc Clin Oncol 2004;22:Abstract No. 8514.

664. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of in-tensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893–899.

665. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99;112–128.

666. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment–cyclophosphamide com-pared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008;26:4385–4393.

667. Sasaki F, Matsunaga T, Iwafuchi M, et al. Outcome of hepatoblastoma treat-ed with the JPLT-1 (Japanese Study Group for Pediatric Liver Trauma) Pro-tocol-1: a report from Japanese Study Group Pediatric Liver Tumor. J Pediatr Surg 2002;37(6):851–856.

668. Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastoma treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: Report from the JPLT. Pediatr Surg Int 2011; 27:1–8.

630. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative che-motherapy in hepatoblastoma. Lancet Oncol 2000;1:94–100.

631. Evans AE, Land VJ, Newton WA, et al. Combination chemotherapy (vincris-tine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. Cancer 1982;50:821–826.

632. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol 1993;11:96–99.

633. Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubi-cin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol 1991;9:2167–2176.

634. von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifos-famide, cisplatin and doxorubicin in the treatment of childhood hepatoblas-toma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997;33:1243–1249.

635. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresect-able and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol 2002;20:3438–3444.

636. Fuchs J, Bode U, von Schweinitz D, et al. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in ad-vanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94. Klin Padiatr 1999;211:305–309.

637. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815–1824.

638. Zsiros J, Brugieres L, Brock P, et al. Efficacy of irinotecan single drug treat-ment in children with refractory or recurrent hepatoblastoma—a phase II trial of the childhood liver tumour strategy group (SIOPEL). Eur J Cancer 2012;48:3456–3464.

639. Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 2006;24:2879–2884.

640. Malogolowkin MH, Katzenstein HM, Krailo M, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 2008;26:2379–2383.

641. Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediat-ric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer 2010;116:4882–4891.

642. Olson TA, Schneider D, Perlman EJ. Germ cell tumors. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams and Wilkins; 2011: 1045–1067.

643. Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for unde-scended testis and risk of testicular cancer. N Engl J Med 2007;356:1835–1841.

644. Schneider DT, Calaminus G, Koch S, et al. Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor proto-cols. Pediatr Blood Cancer 2004;42:169–175.

645. Frazier AL, Rumcheva P, Olson T, et al. Application of the adult internation-al germ cell classification system to pediatric malignant non-seminomatous germ cell tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2008;50:746–751.

646. Einhorn LH. Chemotherapy of disseminated germ cell tumors. Cancer 1987;60:570–573.

647. Ablin AR, Krailo MD, Ramsay NK, et al. Results of treatment of malignant germ cell tumors in 93 children: a report from the Childrens Cancer Study Group. J Clin Oncol 1991;9:1782–1792.

648. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of com-bination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study—Pediatric Oncology Group 9049 and Children’s Cancer Group 8882. J Clin Oncol 2004;22:2691–2700.

649. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not pro-tect against the ototoxicity of high-dose cisplatin combined with etoposide


chapter 99 — references - health library self serve/ppo10e... · r338 chapter 99 references 62....

Documents